Allianz SE Buys Shares of 48,000 Fortrea Holdings Inc. $FTRE

Allianz SE purchased a new position in Fortrea Holdings Inc. (NASDAQ:FTRE) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 48,000 shares of the company’s stock, valued at approximately $404,000. Allianz SE owned approximately 0.05% of Fortrea as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in FTRE. Allworth Financial LP boosted its holdings in Fortrea by 6,802.4% in the second quarter. Allworth Financial LP now owns 5,660 shares of the company’s stock worth $28,000 after acquiring an additional 5,578 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Fortrea by 214.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 3,341 shares of the company’s stock worth $28,000 after purchasing an additional 2,278 shares in the last quarter. Osaic Holdings Inc. grew its position in Fortrea by 74.3% during the 2nd quarter. Osaic Holdings Inc. now owns 6,844 shares of the company’s stock valued at $38,000 after purchasing an additional 2,918 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Fortrea by 137.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,713 shares of the company’s stock valued at $43,000 after purchasing an additional 5,036 shares in the last quarter. Finally, Ameritas Investment Partners Inc. purchased a new position in Fortrea in the second quarter worth about $46,000.

More Fortrea News

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Management said full‑year revenue and adjusted EBITDA delivered in line with targets and that full‑year cost savings exceeded prior targets — a reassurance on operational execution. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance
• Positive Sentiment: Robert W. Baird kept an “outperform” rating and a $16 price target (implying ~49% upside vs. current levels), signaling some analysts remain bullish on the company’s longer‑term outlook. Baird price target note
• Neutral Sentiment: Several full transcripts and earnings‑call highlights were published (useful for parsing management commentary and client/contract trends), giving investors primary‑source detail on drivers and margin dynamics. Fortrea Holdings Inc (FTRE) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst coverage remains active — a recent Benzinga roundup reviews seven ratings, which can amplify volatility as differing views are disseminated. Deep Dive Into Fortrea Holdings Stock: Analyst Perspectives (7 Ratings)
• Negative Sentiment: Q4 results missed consensus: reported EPS $0.09 vs. $0.16 expected, and revenue $660.5M vs. ~$665M expected — the headline misses are driving the immediate negative reaction. Fortrea Q4 Earnings and Revenues Lag Estimates (Zacks)
• Negative Sentiment: Barclays cut its price target to $12 and set an “equal weight” rating — a formal shift toward neutrality/less bullishness that can pressure sentiment and weaken near‑term buyer conviction. Barclays price target cut
• Negative Sentiment: FY‑2026 revenue guidance was given in a range (~$2.6B–$2.7B), which sits slightly below consensus at the top end — the cautious top‑line outlook and an unclear EPS guide left some investors wanting more upside visibility. Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance

Fortrea Price Performance

Shares of NASDAQ:FTRE opened at $10.72 on Friday. The firm’s 50 day moving average price is $15.14 and its 200-day moving average price is $12.34. Fortrea Holdings Inc. has a twelve month low of $3.97 and a twelve month high of $18.67. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.81. The stock has a market capitalization of $990.53 million, a PE ratio of -0.98, a price-to-earnings-growth ratio of 0.33 and a beta of 1.59.

Fortrea (NASDAQ:FTRE) last announced its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.07). Fortrea had a negative net margin of 36.21% and a positive return on equity of 5.97%. The business had revenue of $660.50 million for the quarter, compared to the consensus estimate of $665.22 million. Equities research analysts expect that Fortrea Holdings Inc. will post 0.51 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently commented on FTRE. TD Cowen increased their price target on shares of Fortrea from $7.00 to $15.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. Barclays lowered their price objective on Fortrea from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Fortrea in a report on Thursday, January 22nd. Wedbush set a $21.00 price target on Fortrea in a report on Thursday, December 11th. Finally, Evercore set a $25.00 price objective on Fortrea and gave the stock an “outperform” rating in a report on Tuesday, January 6th. Four investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Fortrea has an average rating of “Hold” and a consensus target price of $16.15.

Fortrea Company Profile

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.